Liver abscesses in adult patients with and without diabetes mellitus: an analysis of the clinical characteristics, features of the causative pathogens, outcomes and predictors of fatality: a report based on a large population, retrospective study in China  by Tian, L.-T. et al.
Liver abscesses in adult patients with and without diabetes mellitus:
an analysis of the clinical characteristics, features of the causative
pathogens, outcomes and predictors of fatality: a report based on a
large population, retrospective study in China
L.-T. Tian1, K. Yao2, X.-Y. Zhang3, Z.-D. Zhang3, Y.-J. Liang1, D.-L. Yin1, L. Lee1, H.-C. Jiang1 and L.-X. Liu1
1) Department of General Surgery, the First Afﬁliated Hospital of Harbin Medical University, 2) Department of Pathology, the First Afﬁliated Hospital of Harbin
Medical University and 3) Department of General Surgery, the Third Afﬁliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China
Abstract
In China, there are four types of liver abscesses (LAs) that meet the clinical criteria. Pyogenic liver abscesses (PLAs) and amoebic liver
abscesses (ALAs) are two of the most common types of abscesses, followed by fungal liver abscesses (FLAs) and hydatid secondary liver
abscesses (HsLAs). Diabetes mellitus (DM) is associated with the development of PLAs. However, there is a lack of population-based stud-
ies that have evaluated the underlying relationship between LAs (mainly PLAs and FLAs) and DM. We conducted a retrospective study
based on a large population to identify the potential differences and factors that affect the mortality of PLA patients in DM and non-DM
groups. Our results revealed that the prevalence of DM is 44.3% (158/357) in PLA patients and 35.3% (18/51) in FLA patients. Compared
with the non-DM patients, statistically signiﬁcant differences were found in DM patients according to symptomatology, clinical manifesta-
tions, laboratory ﬁndings, microbiological characteristics, antimicrobial resistance, clinical treatments and outcomes in relation to mortality.
In addition, the status of antibiotic resistance to E. coli and K. pneumoniae, which were isolated from the patient samples, is severe in the
area in which the study was conducted. Regarding the treatment of PLAs, our study indicated that broad-spectrum antimicrobial therapy
and drug combinations should be recommended and initiated before the pathogens are cultured and identiﬁed. In the clinic, therapies that
combine percutaneous drainage with antibiotics and surgery with antibiotics are the two most useful strategies for treating an LA. These
two combined treatments resulted in satisfactory cure rates. In the DM and non-DM groups, the cure rates for percutaneous drainage
with antibiotics were 90.3% and 92.0%, respectively, and the cure rates for surgery with antibiotics were 93.9% and 95.2%, respectively.
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Introduction
A liver abscess (LA) is a common and potentially life-threat-
ening disease in China and throughout the world, with an
increasing incidence [1]. LAs often manifest as the result of
an emerging infectious disease, which is typically associated
with severe morbidity and mortality around the world. In
China, the two most common types of LAs that have been
observed in clinics are PLAs and ALAs. There is signiﬁcant
regional distribution of LAs all over the world; however, LAs
are common throughout the world, with an incidence that
varies from 0.006% to 2.2% of hospital admissions [2]. The
incidence rate of hospitalization for an LA is different
worldwide and increases annually. In Denmark and Canada,
the incidence rate of PLAs was 1.1–2.3 cases per 100 000
individuals [3,4]. In the United States, the incidence rate
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increased signiﬁcantly from 2.7 to 4.1 cases per 100 000 indi-
viduals from 1994 to 2005 [1], and in Taiwan, the rate was
17.6 per 100 000 individuals [5]. The overall incidence of all
of the types of LAs in the United States has been estimated
to be 5–20 cases per 100 000 individuals. PLA cases repre-
sent approximately 80% of the LA cases in the United States
and in Western countries; superinfection and ALA cases
each represent 10% of the cases, and fungi and other organ-
isms represent <10% of the cases [6]. Many studies have
been conducted on LAs and their pathology, clinical treat-
ments and outcomes [1–4,6]; however, there have been no
correlative reports on the status of LAs in China, and the
impact of this disease is unclear.
Patients with DM are at an increased risk of bacterial
infection [7], which is a signiﬁcant cause of clinical mortality
among DM patients. DM, malignancy, renal disease and pneu-
monia are associated with a higher risk of LAs [5], and DM
is a well-established risk factor for PLAs; however, little is
known about the inﬂuence of DM on PLAs. Many studies
have indicated that DM is a predisposing factor for PLAs,
and patients with DM are more prone to developing PLAs
than patients without DM [8–11]. Excluding PLAs, the preva-
lence and clinical features of other types of LAs (ALAs, FLAs
and HsLAs) in DM and non-DM patients have not been
described. A few studies have analyzed and compared the
clinical characteristics and features of the causative patho-
gens of LAs in patients with DM and without DM [12].
Because there have been few clinical cases, most of the stud-
ies are case reports, and no studies have assessed bacterial
culture and antimicrobial resistance in PLA patients with and
without DM. In China, the annual incidence and clinical fea-
tures of LAs need to be delineated.
More than 100 LA patients are admitted to our hospital
(The First Afﬁliated Hospital of Harbin Medical University,
FAH-HMU) annually. The FAH-HMU is an over 3000-bed
teaching medical centre located in northeast China. We con-
ducted a retrospective study on LA patients, including a
comparison of the demographic characteristics, symptom-
atology, clinical manifestations, laboratory and imaging ﬁnd-
ings, microbiology of pathogenic bacteria, antimicrobial
resistance testing, clinical outcomes and factors in relation to
mortality between PLA patients who were assigned to DM
and non-DM groups. In addition, we compared the treat-
ments, clinical outcomes and mortality rates of FLA patients
in the DM and non-DM groups. Parameters, such as the
morbidity that is associated with all of the types of LAs, the
characteristics of the pathogenic bacteria, liver function,
clinical signs and symptoms, outcomes, such as the length of
hospital stay, procedure-related complications and treatment
failure or death were analysed.
Materials and Methods
Study design
A retrospective study based on a large population was
conducted from February 2005 to August 2009.
Study patients and inclusion criteria
The medical ethics committee at FAH-HMU approved the
protocol for the retrospective study, and all of the patients
were informed of the retrospective review and signed
informed consent forms before the clinical data were col-
lected. All of the patients were over 16 years of age without
gender or race restrictions. We retrospectively reviewed
the medical and microbiological records of all of the patients
who were hospitalized due to LAs and were treated at FAH-
HMU from February 2005 to August 2009. Importantly,
when the patients recovered, died or left the hospital, the
discharged diagnoses were LAs, including PLAs, ALAs, FLAs
and HsLAs, according to the medical records.
The patients who were included in our study met the fol-
lowing criteria: (i) a patient received complete and systematic
treatment at FAH-HMU, and the medical ﬁles were com-
plete; (ii) an LA was the primary cause of the hospitalization
and treatment of a patient but not a complication; (iii) LAs
that were primarily induced by a liver tumour or metastasis
tumour were obviated; and (iv) no other extra-hepatic
abdominal abscesses coexisted in the patient. After applying
the inclusion and exclusion criteria to our study, a total of
596 patients were eligible for further analysis. A total of 16
LA patients were excluded from the study because their
medical treatment data were missing. A total of 23 LA
patients were obviated because they were transferred to dif-
ferent hospitals without receiving complete treatment at
FAH-HMU. Most of the patients were from the Heilongjiang
Province, Inner Mongolia and the Jilin Province.
A diagnosis of a PLA was deﬁned as the following: (i) the
presence of the typical clinical manifestations of infection, such
as leukocytosis, fever, bacteraemia or sepsis and right upper
abdominal pain; (ii) imaging evidence, including ultrasonogra-
phy (US), computerized tomography (CT) or both US and CT
and magnetic resonance imaging (MRI), and positive US-guided
or CT-guided aspiration that was consistent with a PLA; (iii)
laboratory ﬁndings, including white blood count, neutrophil
granulocyte count, abnormal liver function and blood or pus
culture; (iv) surgical ﬁndings; and (v) resolution of the lesion
after experiential therapy with antibiotics if irrefutable evi-
dence from the cultures or surgery was initially lacking.
A diagnosis of an ALA was deﬁned as the following: (i) the
presence of the typical clinical manifestations of amoebic
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infection, such as leukocytosis, high fever, right upper
abdominal pain and recent diarrhoea; (ii) imaging evidence,
including US, CT or both, and positive US-guided or
CT-guided aspiration that was consistent with an ALA; (iii)
laboratory ﬁndings, including white blood count, neutrophil
granulocyte count, abnormal liver function, increased eryth-
rocyte sedimentation rate (ESR), amoeba trophozoites in stools
or in aposematic material, positive ﬁndings on wet mount
examinations or an entamoeba indirect haemagglutination test
(E. IHA) antibody titre >1:75; (iv) surgical ﬁndings; and (v) reso-
lution of the lesion after experiential therapy with antiamoebic
drugs if irrefutable evidence was lacking in the results.
A diagnosis of an FLA was deﬁned as the following: (i) the
presence of the clinical manifestations of fungal infection,
such as leukocytosis, fever and right upper abdominal pain,
which are insensitive to antibiotic treatment; (ii) imaging
evidence, such as abnormal CT, US or MRI; (iii) positive fungal
growth from the abscess or blood cultures; (iv) evidence of
fungal hepatic infection found during the autopsy.
A diagnosis of an HsLA was deﬁned as the following: (i)
the presence of the clinical manifestations of an HsLA, such
as hepatomegaly and right upper abdominal pain, contact
with livestock or house pets, such as a dog, particularly a
shepherd dog, sheep, horse or pig; (ii) imaging evidence, such
as abnormal CT, US or MRI; (iii) increased eosinophil granu-
locyte count, indirect haemagglutination test that is positive
for IgM, positive Weinberg complement ﬁxation test and
positive Casoni test; and (iv) evidence of an HsLA found
during surgery.
The patients who were included in the study were divided
into two groups (a DM group and a non-DM group) accord-
ing to whether they had contracted DM. The deﬁnition of
DM was established according to the following criteria from
1997: a history of DM or the typical symptoms of DM, casual
blood glucose concentrations ‡200 mg/dL, fasting plasma
glucose ‡126 mg/dL, or 2-h plasma glucose ‡200 mg/dL
during an oral glucose tolerance test [13].
Data source
All of the parameters that were included in the investigation
were collected seriatim by reviewing the patient medical
records that were preserved in the medical record library
and the medical computerized database at FAH-HMU. The
patient records were retrospectively examined for the pri-
mary set of data, which included demographic characteristics
(age and sex), clinical parameters (signs and symptoms), labo-
ratory values (haematologic, biochemical and microbiological
ﬁndings), radiological ﬁndings (solitary or multiple abscesses
and lobar distribution), concomitant diseases, diagnoses,
treatment procedures, medications, catheter drainage,
outcomes at discharge (recovered or died), admission and
discharge dates, length of hospital stay and hospital mortality.
All of the diagnoses, concomitant diseases and treatment
procedures in the medical records were coded by the
International Classiﬁcation of Diseases, 9th Version, Clinical
Modiﬁcation (ICD-9-CM). According to the ICD-9-CM diag-
nosis codes, we identiﬁed 357 patients who were discharged
with a diagnosis of a PLA (572.0) during the study period.
When the temperature of a patient was over 38.0C,
blood samples were taken for aerobic and anaerobic cul-
tures. All the drained pus samples were taken for culture
regardless of the patients’ temperatures during their hospital
stays. Upon admission to the hospital, patients were
promptly treated with empirical, broad-spectrum antibiotics
before the initial drainage procedure, depending on the clini-
cal presentation; however, once the results of the culture
and susceptibility tests were obtained, the antibiotic treat-
ment was modiﬁed according to them. Most of the patients
underwent catheter drainage unless the LAs were too small
to require drainage (<3 cm) or there were technical difﬁcul-
ties; however, empirical antibiotics were prescribed to
patients upon admission to the hospital regardless of
whether catheter drains were employed. The drains
remained in place until the convalescent stage. Surgery was
the last treatment option and was performed in several
emergency cases, such as an abscess rupture.
During hospitalization, patient complications, such as a car-
diovascular system occurrence (CVSO), for example acute
coronary artery syndrome, myocardial infarction, hyperten-
sion, lacunar cerebral infarction and haemorrhagic stroke
were analysed. The follow-up of all of the recovered patients
was conducted at outpatient clinics or by telephone or e-mail.
Recurrence was concluded when a patient returned to the
hospital because of an LA within 1 year of discharge.
The microbiological parameters that were included in our
study consisted of polymicrobial infection, monomicrobial
infection (K. pneumoniae or E. coli), anaerobic infection,
bacteraemia and multidrug-resistant (MDR) isolates. Polymi-
crobial infection was deﬁned as the presence of two or
more pathogens that were cultured from blood or pus speci-
mens. Anaerobic infection was concluded when anaerobic
isolates were cultured from blood or pus. MDR was deﬁned
as resistance to three or more of the antimicrobial classes.
An abscess specimen was obtained using the following inva-
sive procedures: image-guided (US or CT) percutaneous nee-
dle aspiration (PNA), image-guided percutaneous catheter
drainage (PCD) or a surgical approach. All of the pus and
blood specimens were processed for bacterial culture and
Gram stain. The isolated pathogens were tested for antimi-
crobial susceptibility.
E316 Clinical Microbiology and Infection, Volume 18 Number 9, September 2012 CMI
ª2012 Lianxin Liu
ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E314–E330
Because PLAs account for a large proportion of LAs and
K. pneumoniae and E. coli were the two most common patho-
genic bacteria at the clinic, we focused on understanding
PLAs and the microbiological characteristics of these two
cultured bacteria. To provide guidance to clinicians on utiliz-
ing antibiotics for the treatment of PLAs, we detected
extended-spectrum b-lactamase (ESBL) in the isolated strains
of E. coli and K. pneumoniae using an ATB microbiological sys-
tem. We selected the Kirby-Bauer (K-B) method for the
antimicrobial susceptibility testing. The results were evalu-
ated according to the National Committee for Clinical Labo-
ratory Standards (NCCLS, USA, 2005), and WHONET 5
was employed to analyse the drug sensitivities to the E. coli
and K. pneumoniae strains that were isolated from the pus
and blood cultures.
Regarding mortality, a logistic regression model was
developed to analyse the relationship between the signiﬁcant
variables (such as diabetes mellitus, Gas-forming, polymicro-
bial infection, multidrug resistance, and so on) and mortality.
The symptoms and signs were excluded from the analysis
because the characteristics of these data were subjective.
Statistical analysis
The statistical analysis was performed using the SAS statisti-
cal software package (SAS, version 9.1; SAS Institute Inc.,
Cary, NC, USA). The descriptive data were presented as the
means with standard deviations (SDs) for the continuous
data and as percentages for the categorical data. The
chi-squared test or Fisher’s exact test were used to evaluate
the differences in the categorical variables; Student’s t-test
was used to evaluate the differences in the continuous vari-
ables. A logistic regression model was developed to identify
the independent prognostic factors that were associated with
mortality. The odds ratios (ORs) and 95% conﬁdence inter-
vals (95% CIs) were estimated in the logistic regression
model. p <0.05 was considered statistically signiﬁcant in all of
the analyses. All of the p values were two tailed.
Results
Characteristics of the patients and descriptive tables and
data
Overall, a total of 596 medical records of patients who were
discharged with a diagnosis of an LA or a diagnosis that was
related to an LA were retrieved. After excluding 39 patients
whose medical data were incomplete, a total of 557 patients
who met the selection criteria were included in the ﬁnal
analysis. None of the patients was seropositive for HIV. Of
the 557 patients who were included in the analysis, 238
(42.7%) patients had DM. The cohort was mainly composed
of four types of LAs, including PLAs, ALAs, FLAs and HsLAs.
The demography of the LA cases and the numbers of our
study subjects are listed in Table 1. The results of the study
are expounded in sequence.
Pyogenic liver abscess
Patient demographic data, recent medical history, pathogenesis,
complications, lesion size and location.
Excluding the patients who did not meet the inclusion crite-
ria, a total of 357 patients who were ‡16 years of age
received complete treatment for a PLA during the study
period. Of the included PLA patients, 158 (44.3%) patients
had DM, and 201 patients were male (male-to-female ratio,
1.29:1.0). Among the diabetic PLA patients, 28 (17.7%)
patients were diagnosed with DM during their hospitalization
for a PLA. None of the patients had developed ketoacidosis
after admission according to the medical records. The 357
patients with a PLA represented approximately 0.16% of the
patients who were admitted to the hospital (160 cases per
100 000 admissions) during the period. We found that more
co-morbidities were present in diabetic patients than in
non-diabetic patients, such as a higher prevalence rate of the
common cold within 2 weeks before admission according to
the personal histories. Compared with the DM group, PLA
patients without DM were more prone to coexisting malig-
nancy, and these patients had lower prevalence rates of
coexisting cardiovascular system diseases. The most frequent
aetiopathogenesis of a PLA in both groups was a cryptogenic
origin; however, this origin was more common in the DM
group. A biliary origin (biliary calculi and/or cholecystolithiasis)
was the second most common aetiology; however, the fre-
quency of this origin was less in the DM group than in the
non-DM group. The differences in the sizes and locations of
the LA lesions between the two groups were statistically
signiﬁcant. Moreover, the DM group had a higher prevalence
of a gas-forming PLA (p 0.026), and the patients with DM had a
greater tendency to have multiple abscesses (p 0.023). The
TABLE 1. Demographic characteristics of the liver abscesses
in patients with diabetes mellitus (DM) and without diabetes
mellitus (non-DM)
Liver abscess
type
DM cases
(%)
Non-DM
cases
p value
(v2-test)
PLA 158 199
Male 93 (58.9) 108 (54.3) 0.385
ALA 11 95
Male 7 (63.6) 69 (72.6) 0.502
FLA 18 33
Male 8 (44.4) 17 (51.5) 0.629
HsLA 15 28
Male 6 (40.0) 10 (35.7) 0.782
Total 202 (36.3) 355 (63.7) –
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rates of MODS and abscess recurrence were higher in the
DM group than in the non-DM group. Statistically signiﬁcant
differences were found between the DM and non-DM groups
according to the duration of stay in the intensive care unit
(ICU-T) and the total average febrifacient time (t-AFT). In
addition, patients who developed a PLA after blunt abdomi-
nal traumas, such as vehicle collisions, that caused liver lacer-
ations were classiﬁed as ‘liver traumas’. Two patients
developed a PLA after percutaneous transhepatic cholangiog-
raphy and drainage, and these patients were classiﬁed as
‘other’. (Table 2).
Patient clinical symptoms and signs.
The most common symptoms of a PLA were fever and chills
in both groups, followed by right upper quadrant (RUQ)
pain, nausea and vomiting and general weakness. The preva-
lence rates of the other symptoms and signs listed in Table 2
were under 20%. More PLA patients with DM had tempera-
tures >38.5C than patients without DM (p 0.035). Nausea
and vomiting were more common in the DM group than in
the non-DM group (p 0.005). In addition, the DM patients
had higher prevalence rates of systemic inﬂammatory
response syndrome (SIRS, p 0.044) and shock (p 0.026) dur-
ing hospitalization. (Table 3).
Patient laboratory and imaging ﬁndings.
The following blood test ﬁndings were similar for most of
the patients in both groups: leukocytosis (always with a left
shift), changes in haemogram, abnormal liver function and
anaemia. We detected ﬁve biochemical indicators, such as
leukocytosis, blood urea nitrogen (BUN), creatinine (Cr),
hypoproteinaemia and temporarily increased ESR, which
demonstrated statistically signiﬁcant differences between the
two groups. A higher incidence of anaemia, neutrophilic ple-
ocytosis, prolonged prothrombin time (PT) and elevated
AST and/or ALT levels was detected in both groups; how-
ever, there were no statistical differences. Additionally,
increased serum levels of alkaline phosphatase (ALP) and
gamma-glutamyltransferase (GGT) were observed in more
than 50% of the patients in both groups; however, the differ-
ence was not statistically signiﬁcant. Remarkably, the sensitiv-
ity of the cross-reacting protein (CRP) was approximately
100% in all of the PLA patients. All of the diagnostic modali-
ties (US, CT or MRI) that were employed for a PLA had a
sensitivity of over 95% in both groups of patients. (Table 4).
Patient microbiological ﬁndings and the status of antibiotic
resistance in the cultured bacteria.
Microbiological ﬁndings: Pus cultures were collected in 86.3%
((140 + 168)/357) of the patients, and the overall positive
growth rate was 91.2% ((131 + 150)/(140 + 168)). The posi-
tive growth rates in the DM and non-DM groups were
93.6% and 89.3%, respectively. The overall rate of polymicro-
bial growth in the pus cultures was 9.7% ((16 + 14)/
(140 + 168)), and the rates in the DM and non-DM groups
were 12.2% and 9.3%, respectively; however, the difference
was not statistically signiﬁcant. During hospitalization, when
the temperature of a patient was over 38.0C, blood
TABLE 2. Characteristics of the recent patient histories
before admission, pathogenesis and complications during
hospitalization of PLA patients with diabetes mellitus and
without diabetes mellitus (non-DM)
Characteristics/
Demographics
DM cases
158 (%)
Non-DM
cases
199 (%)
p value
(v2-test)
Age (year, mean ± SD) 63.8 ± 15.7 57.2 ± 16.3 0.024a
PMH (within 2 weeks)
Common cold 16 (10.1) 9 (4.5) 0.039
URTI 5 (3.2) 7 (3.5) 0.854
Community-acquired
pneumonia
4 (2.5) 6 (3.0) 1.0b
Steroid use 5 (3.2) 4 (2.0) 0.517b
ISA use 2 (1.3) 3 (1.5) 1.0b
Malignancy 6 (3.8) 18 (9.0) 0.049
Radiotherapy 1 (0.6) 4 (2.0) 0.388b
Chemotherapeutics 7 (4.4) 11 (5.5) 0.638
Uraemia 5 (3.2) 7 (3.5) 0.854
Hepatitis (HB or HC) 11 (7.0) 15 (7.5) 0.835
Liver cirrhosis 9 (5.7) 13 (6.5) 0.744
Hepatic cyst 6 (3.8) 1 (0.5) 0.047b
Biliary tract disease 27 (17.1) 23 (11.6) 0.135
Appendicitis 2 (1.3) 2 (1.0) 1.0b
Other – – NS
Pathogenesis
Cryptogenic 124 (78.5) 120 (61.3) <0.001
BC or CC 10 (6.3) 46 (23.1) <0.001
SSTIs 9 (5.7) 7 (3.5) 0.323
Furuncle or carbuncle 5 (3.2) 4 (2.0) 0.517b
Direct invasion 2 (1.3) 3 (1.5) 1.0b
Liver trauma 4 (2.5) 3 (1.5) 0.70b
Other 4 (2.5) 16 (8.0) NS
Abscess location
Right lobe 80 (50.6) 117 (58.8) 0.018
Left lobe 40 (25.3) 57 (28.6)
Bilobar involvement 38 (24.1) 25 (12.6) 0.005
Abscess size
Single abscess
<5 61 (38.6) 104 (52.3) 0.029
5–10 50 (31.6) 58 (29.1)
>10 20 (12.7) 19 (9.5)
Multiple abscesses 27 (17.1) 18 (9.1) 0.023
Gas-forming 18 (11.4) 10 (5.0) 0.026
COMP during DHS
CVS occurrence 28 (17.7) 19 (9.5) 0.023
Reactive pleural ﬂuid 11 (7.0) 15 (7.5) 0.835
Bacteraemia 77 (48.7) 89 (44.7) 0.450
Septic shock 9 (5.6) 13 (6.5) 0.744
Ascites 4 (2.5) 7 (3.5) 0.761b
ARF 3 (1.9) 4 (2.0) 1.0b
MODS 12 (7.6) 6 (3.0) 0.049
RC-A 20 (12.7) 13 (6.5) 0.047
t-AFT 15.4 ± 5.7 12.8 ± 9.6 0.012a
ICU-T 6.2 ± 3.9 4.3 ± 1.5 0.021a
SSTIs, skin and soft tissue infections; URTI, upper respiratory tract infection;
CAP, community-acquired pneumonia; BC or CC, biliary calculi or cholecysto-
lithiasis; ISA, immunosuppressive agent; COMP, complication; DHS, duration of
hospital stay; CVS, cardiovascular system; ARF, acute renal failure; MODS,
multi-organ dysfunction syndrome; RC-A, recurrence of the abscess; t-AFT,
total average fever time; ICU-T, stay in intensive care unit (days); NS, not
signiﬁcant.
aStudent’s t-test.
bFisher’s exact test.
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specimens were collected for anaerobic and/or aerobic
cultures. The overall positive growth rate was 63.5%
((68 + 52)/(92 + 97)) in the blood cultures, and the positive
growth rates in the DM and non-DM groups were 73.9%
and 53.6%, respectively. The differences were statistically
signiﬁcant (p 0.004). A small proportion (5.3%, (6 + 4)/
(92 + 97)) of the culture-positive patients had polymicrobial
growths, and the number of bacteria that were isolated from
the blood cultures was less than that from the pus cultures.
Of the pathogens that were identiﬁed in the blood cultures
of both groups, K. pneumoniae was the most commonly
isolated pathogen, followed by E. coli. In the pus cultures of
the DM group, K. pneumoniae was predominant, followed by
E. coli and anaerobes, whereas E. coli and Viridans streptococci
were the second and third most commonly isolated patho-
gens in the non-DM group. Anaerobes were only cultured
and isolated from the pus specimens, and the growth rate of
the anaerobes in the DM group was greater than that in the
non-DM group. Conversely, the growth rate of Viridians
streptococci in the pus and blood cultures in the non-DM
group was greater than that in the DM group. The preva-
lence of other cultured bacteria was <5%, and we did not
perform any further analysis (Tables 5 and 6).
Antibiotic resistance: In total, 338 bacterial pathogens (53
E. coli and 285 K. pneumoniae), which were cultured and iso-
lated from PLA specimens, were analysed. We reviewed the
patient medical records to obtain the results of the antimi-
crobial resistance testing. The state of antimicrobial resis-
tance of cultured and isolated pathogens is very serious. The
results of the susceptibility and resistance testing for the bac-
teria that were isolated from the specimens of both groups
were examined.
The isolated E. coli strains were resistant to most of the
common antibiotics that were used at the clinic and the rate of
TABLE 3. Symptomatology of PLA patients with diabetes
mellitus and without diabetes mellitus (non-DM)
Symptoms and signs
DM cases
158 (%)
Non-DM
cases
199 (%)
p value
(v2-test)
Symptoms
Fever/chills 136 (86.1) 180 (90.5) 0.198
Cough/dyspnoea 13 (8.2) 16 (8.0) 0.949
General weakness 18 (11.4) 25 (12.6) 0.736
Hiccups 4 (2.5) 4 (2.0) 0.736a
Nausea/vomiting 36 (22.8) 23 (11.6) 0.005
Pleuritic/chest pain 9 (5.7) 12 (6.0) 0.894
RUQ pain 75 (47.5) 104 (52.3) 0.368
Abdominal pain 15 (9.5) 20 (10.0) 0.861
Diarrhoea 5 (3.2) 4 (2.0) 0.517a
Weight loss (‡2.5 kg) 11 (7.0) 10 (5.0) 0.440
Signs
Fever (T ‡ 38.5C) 27 (17.1) 19 (9.5) 0.035
Jaundice 6 (3.8) 10 (5.0) 0.578
Rales/rhonchi 11 (7.0) 13 (6.5) 0.872
Hepatomegaly 10 (6.3) 12 (6.0) 0.907
Murphy signs 5 (3.2) 11 (5.5) 0.284
Ascites 15 (8.0) 10 (5.0) 0.100
SIRS 11 (7.0) 5 (2.5) 0.044
Shock 8 (3.8) 2 (2.0) 0.026a
RUQ, right upper quadrant of abdomen; SIRS, systemic inﬂammatory response
syndrome.
aFisher’s exact test.
TABLE 4. Laboratory and imaging ﬁndings of PLA patients
with diabetes mellitus (DM) and without diabetes mellitus
(non-DM)
Characteristics
DM cases
158 (%)
Non-DM
cases
199 (%)
p value
(v2-test)
Laboratory feature
WBCc >10 000/dL 125 (79.1) 138 (69.3) 0.037
WBCc <4000/lL 5 (3.2) 7 (3.5) 0.854
Neutrophil count (>75%) 140 (88.6) 180 (90.1) 0.570
Platelet count (<140 000/dL) 10 (6.3) 19 (9.5) 0.269
Haemoglobin (<12 g/dL) 104 (65.8) 135 (67.8) 0.687
AST >50 IU/L 80 (50.6) 105 (52.7) 0.689
ALT >50 IU/L 89 (56.3) 122 (61.3) 0.342
PT >13.0 s 110 (69.6) 128 (64.3) 0.291
T. Bil >5 mg/dL 75 (47.5) 98 (48.7) 0.738
BUN >22 mg/dL 72 (45.6) 54 (27.1) 0.001
Cr >140 lM 58 (36.7) 52 (26.1) 0.032
CRP >6 mg/L 158 (100) 197 (99.0) 0.505a
Glucose > 120 mg/dL 146 (92.4) 57 (28.6) <0.001
ESR >30 mm/h 64 (40.5) 58 (29.1) 0.025
ALP ‡3-fold 103 (65.2) 121 (60.8) 0.395
GGT ‡3-fold 87 (55.1) 116 (58.3) 0.541
Albumin <35 g/dL 37 (23.4) 27 (13.6) 0.016
Chest X-ray
Pneumonia 12 (7.6) 14 (7.0) 0.840
Right pleural effusion 11 (7.0) 15 (7.5) 0.853
e-RHD 4 (2.5) 5 (2.5) 1.0a
Abnormal image (liver)
Sonography 133/138 (96.4) 173/182 (95.1) 0.567
CT 118/120 (98.3) 140/143 (97.9) 1.0a
MRI 68/70 (97.1) 83/85 (97.6) 1.0a
WBCc, white blood cell count; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; PT, prothrombin time; T. Bil, total bilirubin; BUN, blood urea
nitrogen; Cr, creatinine; CRP, cross-reacting protein; ESR, erythrocyte sedimen-
tation rate; ALP, alkaline phosphatase; GGT, gamma glutamyl transpeptidase;
e-RHD, elevated right hemidiaphragm; CT, computed tomography; MRI,
magnetic resonance imaging.
aFisher’s exact test.
TABLE 5. Microbiological characteristics of PLA patients
with diabetes mellitus (DM) and without diabetes mellitus
(non-DM) during hospitalization: pus cultures
Characteristics
DM cases
140 (%)
Non-DM
cases
168 (%)
p value
(v2-test)
Positive growth 131 (93.6) 150 (89.3) 0.185
Polymicrobial growth 16 (12.2) 14 (9.3) 0.362
Klebsiella pneumonia 115 (87.8) 109 (72.7) 0.001
Klebsiella oxytoca 5 (3.8) 7 (4.7) 0.788
Anaerobe 9 (6.9) 2 (1.3) 0.014a
Bacteroides fragilis 1 (0.8) 1 (0.7) 1.0a
Escherichia coli 16 (12.2) 22 (14.7) 0.658
Staphylococcus aureus 4 (3.1) 4 (2.7) 1.0a
Viridians streptococcus 3 (2.3) 13 (8.7) 0.028
Pseudomonas aeruginosa 3 (2.3) 4 (2.7) 1.0a
Enterobacter faecalis 2 (1.5) 6 (4.0) 0.299a
Proteus mirabilis 2 (1.5) 3 (2.0) 1.0a
Enterococcus species 1 (0.8) 0 (0) 0.455a
Actinomycetes 0 (0) 2 (1.3) 0.503a
Others – – NS
NS, not signiﬁcant.
aFisher’s exact test.
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resistance was remarkably high. The incidence of MDR bacte-
ria in diabetic patients was higher than that in patients without
DM. According to the ESBL test, 62.5% of the isolates were
positive in the DM group, and 24.1% of the isolates were posi-
tive (p 0.005) in the non-DM group. The rate of resistance to
gentamicin was signiﬁcantly different between the DM and
non-DM groups (p 0.011). In addition, differences in the rates
of resistance were found for cefazolin (p 0.004), ciproﬂoxacin
(p 0.014) and trimethoprim/sulfa (p 0.013).
The isolated K. pneumoniae strains were resistant to most
of the common antibiotics that were used at the clinic, with
high rates of resistance. According to the ESBL test, the rates
of positive isolates in the DM and non-DM groups were
52.0% and 27.2%, respectively. The difference was statistically
signiﬁcant (p <0.001). The incidence of drug-resistant bacteria
in the DM group was higher than that in the non-DM group,
and the rate of resistance to antibiotics of the isolated
K. pneumoniae strains was signiﬁcantly different between the
DM and non-DM groups. These differences were presented
as amikacin (p 0.005), cefoperazone/sulbactam (p 0.001),
cefazolin (p <0.001), levoﬂoxacin (p < 0.001) and piperacillin/
tazobactam (p 0.006). In addition, the majority of the K. pneu-
moniae strains that were isolated from the DM group were
found to be resistant to gentamicin (55.1%), cefuroxime
(52.8%), ciproﬂoxacin (63.8%) and piperacillin (76.4%).
Accordingly, the rates of resistance to the four antibiotics in
the non-DM group were lower: gentamicin (51.3%),
cefuroxime (46.2%), ciproﬂoxacin (55.1%) and piperacillin
(67.7%). The data regarding the antimicrobial resistance of
the two isolated bacteria are listed in Tables 7 and 8.
Amoebic liver abscess
During the study period, there were 106 patients over
16 years of age who had received complete treatment for an
ALA at our hospital. Of the ALA patients, 11 (10.4%)
patients had DM, 76 patients were male (male-to-female
ratio, 2.5:1), and the mean age was 43.2 ± 3.2 years. The
mean age of the patients without DM was 40.6 ± 4.1 years.
In the histories of both groups of patients, diarrhoea was
present in 36.4% (4/11) of the DM patients but 15.8% (15/
95) of the non-DM patients; however, the difference was not
TABLE 6. Microbiological characteristics of PLA patients
with diabetes mellitus (DM) and without diabetes mellitus
(non-DM) during hospitalization: blood cultures
Characteristics
DM cases
68 (%)
Non-DM
cases
52 (%)
p value
(v2-test)
Positive growth 68 (68/92,73.9) 52 (52/97,53.6) 0.004
Polymicrobial growth 6 (8.8) 7 (13.5) 0.418
Klebsiella pneumonia 59 (86.8) 39 (75.0) 0.099
Escherichia coli 2 (2.9) 13 (25.0) <0.001a
Proteus mirabilis 1 (1.5) 0 (0) 1.00a
Pseudomonas aeruginosa 0 (0) 2 (3.8) 0.186a
Staphylococcus aureus 2 (2.9) 1 (1.9) 1.0a
Viridians streptococcus 1 (1.5) 4 (7.7) 0.165a
Enterobacter faecalis 1 (1.5) 3 (5.8) 0.315a
aFisher’s exact test.
TABLE 7. Microbiological characteristics of PLA patients
with diabetes mellitus (DM) and without diabetes mellitus
(non-DM) during hospitalization: antibiotic susceptibility and
resistance testing of Escherichia coli
Antibiotic species
DM cases
24 (%)
Non-DM
cases
29 (%)
p value
(v2-test)
ESBL test 15 (62.5) 7 (24.1) 0.005
Plasmid-AmpC-b-lactamases 3 (12.5) 2 (6.9) 0.649a
Metallo-b-lactamases 0 (0) 0 (0) NS
Amikacin 3 (12.5) 3 (10.3) 1.0a
Gentamicin 21 (87.5) 16 (55.2) 0.011
Cefazolin 12 (50.0) 4 (13.8) 0.004
Cefoxitin 18 (75.0) 26 (89.7) 0.271
Cefuroxime 23 (95.8) 27 (93.1) 1.0a
Ceftriaxone 7 (29.2) 5 (17.2) 0.302
Ceftazidime 9 (37.5) 7 (24.1) 0.292
Cefoperazone/sulbactam 4 (16.7) 5 (17.2) 1.0a
Cefepime 9 (37.5) 8 (27.6) 0.441
Ciproﬂoxacin 18 (75.5) 12 (41.4) 0.014
Levoﬂoxacin 20 (83.3) 27 (93.1) 0.392
Imipenem 0 (0) 0 (0) NS
Meropenem 0 (0) 0 (0) NS
Aztreonam 8 (33.3) 7 (24.1) 0.459
Piperacillin 21 (87.5) 22 (75.9) 0.318
Piperacillin/tazobactam 2 (8.3) 2 (6.7) 1.0a
Trimethoprim/sulfa 22 (91.7) 18 (72.4) 0.013
Nitrofurantoin 5 (20.8) 4 (13.8) 0.715a
ESBL test, extended-spectrum b-lactamases test; NS, not signiﬁcant.
aFisher’s exact test.
TABLE 8. Microbiological characteristics of PLA patients
with diabetes mellitus (DM) and without diabetes mellitus
(non-DM) during hospitalization: antibiotic susceptibility and
resistance testing of Klebsiella pneumoniae
Antibiotic species
DM cases
127 (%)
Non-DM
cases
158 (%)
p value
(v2-test)
ESBL test 66 (52.0) 43 (27.2) <0.001
Plasmid-AmpC-b-lactamases 16 (12.6) 12 (7.6) 0.158
Metallo-b-lactamases 0 (0) 0 (0) NS
Amikacin 26 (20.5) 14 (8.9) 0.005
Gentamicin 70 (55.1) 81 (51.3) 0.517
Cefazolin 96 (75.6) 68 (43.0) <0.001
Cefoxitin 38 (29.9) 43 (27.2) 0.615
Cefuroxime 67 (52.8) 73 (46.2) 0.271
Ceftriaxone 33 (26.0) 28 (17.7) 0.091
Ceftazidime 31 (24.4) 27 (17.1) 0.127
Cefoperazone/sulbactam 28 (22.0) 13 (8.2) 0.001
Cefepime 14 (11.0) 12 (7.6) 0.318
Ciproﬂoxacin 81 (63.8) 87 (55.1) 0.137
Levoﬂoxacin 73 (57.5) 41 (25.9) <0.001
Imipenem 8 (6.3) 5 (3.2) 0.207
Meropenem 5 (3.9) 3 (1.9) 0.473a
Aztreonam 9 (7.1) 8 (5.1) 0.473
Piperacillin 97 (76.4) 107 (67.7) 0.107
Piperacillin/tazobactam 21 (16.5) 10 (7.0) 0.006
Trimethoprim/sulfa 91 (71.7) 101 (63.9) 0.167
Nitrofurantoin 67 (52.8) 81 (51.3) 0.802
ESBL test, extended-spectrum b-lactamases test; NS, not signiﬁcant.
aFisher’s exact test.
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statistically signiﬁcant. A difference (18.2% (2/11) vs. 36.8%
(35/95)) in the prevalence of alcohol use was found between
the two groups; however, the difference was not statistically
signiﬁcant. Remarkably, we found that ALAs in diabetic
patients often developed into mixed infections ([45.5% (5/11)
vs. 9.5% (9/95), p 0.006)). The majority of the abscesses in
patients were detected in the right lobe. A single abscess
with a diameter £5 cm was found in more than one-third of
the patients in both groups whereas the prevalence of large
abscesses (a diameter ‡10 cm) in the DM group was higher
than that in the non-DM group (27.3% (3/11) vs. 15.8% (15/
95)). During hospitalization, the prevalence of CVSO in the
DM group was found to be higher than that in the non-DM
group (18.2% (2/11) vs. 5.3% (5/95)), and the difference was
not statistically signiﬁcant. In this report, we only discussed
the demographic characteristics of the patients with an ALA
in both groups. The data regarding the symptomatology and
the laboratory and imaging ﬁndings in both groups would
need to be included in a separate article.
Fungal liver abscess
After a review of the medical records, a total of 51 FLA
patients (male-to-female ratio, approximately 1:1) were
included in this study. The mean ages of the FLA patients in
the DM and non-DM groups were 66.7 ± 10.5 and
65.6 ± 12.9 years, respectively. In both groups, the majority
of the abscesses were located in the right lobe. The diame-
ters of most of the abscesses were <5 cm in both groups.
Approximately one-third (30.3%) of the patients in the non-
DM group had multiple abscesses whereas more than one-
third (38.9%) of the patients in the DM group had multiple
abscesses. In addition, the prevalence of CVSO in the DM
group was higher than that in the non-DM group (27.8% vs.
12.1%). The incidence rates of MODS in the DM and non-
DM groups were high (44.4% vs. 36.4%). The most common
pathogen that was isolated from FLA patients was Candida
albicans, followed by Candida glabrata in the DM group and
Candida mycoderma in the non-DM group. Patients with DM
were more prone to infection with Candida glabrata (38.9%
(7/18) vs. 9.1% (3/33), p 0.023). The data regarding the char-
acteristics of the patients with FLA would need to be
included in a separate article.
In this study, the mortality rate (MR) of the PLA patients
with DM was 7.6%, and the rate was 6.5% in the patients
without DM; however, this difference was not statistically
signiﬁcant. For the PLA patients, there was no statistically
signiﬁcant difference in the achievement ratio of treatment
between the DM and non-DM groups. For the FLA patients,
the mortality rate was 38.9% and 24.2% for the DM group
and non-DM group, respectively; however, this difference
was not statistically signiﬁcant. Similar results were obtained
for the ALA patients, and no statistical differences were
found in the outcomes of the two groups of patients (data
not presented). In the FLA patients, the achievement ratio of
treatment between the two groups was similar, excluding
those patients who had accepted therapeutic alliance
(SG + Ab). The different clinical outcomes in the DM and
non-DM groups corresponded to the different LA types, and
the variations among these types generally inﬂuence the clini-
cal outcome of a patient. We found that DM demonstrated
a negative impact on the clinical outcomes of the PLA and
FLA patients, such as mean draining time (MDT), length of
stay at the hospital and the duration of symptoms. The data
on the MRs, achievement ratios of treatment and the clinical
outcomes of the two groups of patients with PLA and FLA
are shown in Tables 9 and 10.
Discussion
To our knowledge, this is the ﬁrst large population-based ret-
rospective study to investigate the incidence, clinical charac-
teristics, microbiological features and outcomes of PLA
hospitalization for patients with and without DM. This investi-
gation has provided a comprehensive perspective of the mor-
bidity, mortality and clinical and epidemiological
characteristics of PLAs. The results of the analysis of the FLA
and ALA patients will be presented in a separate article. Dur-
ing the study period, the average annual incidence of hospital-
ization for a PLA was approximately 5.7 cases per 100 000
individuals. When ALA, FLA and HsLA cases are combined
with PLA cases, the incidence of LAs increases to 8.9 cases
TABLE 9. Comparison of the treatments, clinical outcomes
and mortality rates (MRs) of PLAs between patients with
diabetes mellitus (DM) and without diabetes mellitus
(non-DM)
MR/Treatments /
Clinical outcomes
DM cases
158 (%)
Non-DM cases
199 (%)
p value
MR 12 (7.6) 13 (6.5) 0.696
Treatments
Ab 21 (13.3) 33 (16.6) 0.389
PD + Ab 113 (71.5) 147 (73.9) 0.620
SG + Ab 24 (15.2) 19 (9.5) 0.104
Outcomes
m-TT 14.5 ± 8.8 10.2 ± 16.7 0.046a
LOS (day) 30.6 ± 17.3 23.2 ± 11.5 0.037a
PS 25.3 ± 13.6 17.1 ± 10.3 0.032a
AAT 22.3 ± 14.3 19.3 ± 11.2 0.622a
MR, mortality rate; Ab, antibiotic; PD, percutaneous tube drainage; SG, surgery;
LOS, length of stay at hospital; PD + Ab, percutaneous tube drainage + antibi-
otic; SG + Ab, surgery + antibiotic; m-TT, mean tubing time; PS, persistence of
symptoms (since patients accepted clinical treatments); AAT, antibiotic adminis-
tration time.
aStudent’s t-test.
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per 100 000 individuals. The incidence rate of PLAs in this
study is higher than that in previously published reports from
Denmark, Canada and the United States, which indicated a
PLA incidence rate of 1.1–3.6 cases per 100 000 individuals
[1,3,4,14]. However, the incidence rate in this study is lower
than that in Taiwan (17.6 cases per 100 000 individuals) [5].
The different aetiological factors for PLAs and the varying
prevalence of disease in the biliary system, such as cholangitis
and biliary calculi, could have caused the variation in the PLA
incidence rates between these countries and China. In addi-
tion, the regional and climatic differences among these coun-
tries could have contributed to this variation. The association
between PLAs and DM has been conﬁrmed in a series of
reports [7,8,12,13]; therefore, the different incidence rates of
PLAs between adult patients in China and other countries
may be the result of a varying prevalence of DM in these
countries. From a clinical perspective, PLAs account for the
highest rate of LAs. PLAs can be frequently observed in out-
patient clinics or emergency departments, and the associated
morbidity and mortality of PLAs exceed those of the other
types of LAs, such as ALAs and HsLAs. Therefore, we aimed
to elucidate the clinical characteristics, aetiological or micro-
biological features and outcomes of PLAs in this study.
According to the results of the retrospective study, there are
notable differences in the clinical characteristics, pathological
changes, complications, microbiological features, outcomes
and predictors of mortality between patients with DM and
patients without DM.
In this study, we found that the mean age of PLA patients
with DM was approximately 6 years greater (p 0.024) than
that of patients without DM. The effect of ageing on the
incidence of DM could have led to this difference. The mean
age of most of the PLA patients was >57 years (diabetic
patients, 63 years), which suggests that PLAs could be con-
sidered a type of senile disease. The elderly and individuals
of advanced age are more susceptible to immune deteriora-
tion and increased morbidity, which may predispose them to
PLAs, such as those that are associated with DM, cardiovas-
cular disease and chronic obstructive pulmonary disease. Fur-
thermore, these diseases in the elderly are usually long-term
diseases, which may have a signiﬁcantly negative effect on
patient health. The relationship between decreased immunity
and DM was demonstrated by the higher prevalence of the
common cold in PLA patients with DM (p 0.039). DM is a
risk factor for cardiovascular disease, and we found that dia-
betic PLA patients were more likely to develop CVSO than
non-diabetic PLA patients (p 0.023). Similar to the results in
previously published reports [7,8,12], our results suggest that
DM is a risk factor for PLAs. Patients with DM (previously
known or newly diagnosed) or any other underlying immu-
nocompromised conditions, such as malignancy, viral infec-
tion or post-chemotherapy/radiotherapy, were more prone
to develop a PLA than patients without them. Additionally,
we observed that the male predominance in both of the PLA
groups was consistent with previous reports [3,4,15–17].
After reviewing the correlative reports and integrating the
results from this study, we conclude that the pathogenesis of
PLAs has changed over the past decades. Previously, pyle-
phlebitis and biliary disease were the two most common
aetiologies of PLAs, but the incidence of these diseases has
been decreasing [15]. In this study, cryptogenic infection was
the most frequent aetiopathogenesis of PLAs, and this ﬁnding
is consistent with previous reports [3,12,15,18]. DM inter-
feres with neutrophil chemotaxis and phagocytosis [19–22];
however, the inﬂuence of DM on the function of macrophag-
es remains unknown. In the recent histories (within 2 weeks)
of the PLA patients, we found that the common cold was
more frequent in the DM group than in the non-DM group
but that malignancy was signiﬁcantly more prevalent in the
non-DM group than in the DM group (p 0.049). PLAs usually
develop in immunocompromised patients; therefore, the
acquisition of the common cold may be a signal of temporary
immunodeﬁciency. From a clinical perspective, PLAs can be a
secondary infection to a hepatic cyst, especially when patient
immunity is insufﬁcient, and DM contributes to the develop-
ment of hepatic cysts into PLAs in immunocompromised
individuals. This ﬁnding may explain why hepatic cysts were
more common in the DM group than in the non-DM group.
(Table 2).
Regarding pathogenesis, we found that cryptogenic PLAs
accounted for most of the LAs in the cohort; however, the
TABLE 10. Comparison of the treatments, clinical out-
comes and mortality rates (MRs) of FLAs between patients
with diabetes mellitus (DM) and without diabetes mellitus
(non-DM)
MR/Treatments /
Clinical outcomes
DM cases
18 (%)
Non-DM cases
33 (%)
p value
MR 7 (38.9) 5 (24.2) 0.085
Treatments
Ab 2 (11.1) 2 (6.1) 0.607a
PD + Ab 11 (61.1) 12 (36.4) 0.090
SG + Ab 5 (27.8) 19 (57.6) 0.042
Outcomes
m-TT 32.5 ± 17.3 26.3 ± 15.7 0.037b
LOS (day) 42.3 ± 25.6 34.7 ± 21.2 0.030b
PS 30.4 ± 18.5 28.7 ± 17.2 0.043b
AAT 37.9 ± 19.3 30.8 ± 18.6 0.052b
MR, mortality rate; Ab, antibiotic; PD, percutaneous tube drainage; SG, surgery;
LOS, length of stay at hospital; PD + Ab, percutaneous tube drainage + antibi-
otic; SG + Ab, surgery + antibiotic; m-TT, mean tubing time; PS, persistence of
symptoms (since patients accepted clinical treatments); AAT, antibiotic adminis-
tration time.
aFisher’s exact test.
bStudent’s t-test.
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rate of PLAs in the DM group was higher than that in the
non-DM group. Biliary calculi and/or cholecystolithiasis were
more common in the non-DM group, which may correlate
with the high prevalence of biliary tract diseases in the non-
DM group. The results of this study are consistent with the
results in previously published reports [12]. Distant metasta-
sis is a major origin of PLAs, and skin and soft tissue infec-
tions (SSTIs) are a source of distant metastasis. Patients with
DM are prone to developing infective diseases, such as SSTIs,
furuncles and carbuncles, which were found in both groups
in this study. A greater number of these diseases were found
in the DM group; however, there were no statistically signiﬁ-
cant differences between the two groups. (Table 2).
The majority of PLAs were located in the right hepatic
lobe, which may be relevant to its anatomical position, size
and propensity to receive the greatest amount of portal
blood ﬂow and lymphatic return. Compared with non-DM
patients, bilobar involvement was detected in more diabetic
patients, and the difference was statistically signiﬁcant. In this
study, we found that the sizes of most of the LAs were
<10 cm. Compared with the non-DM group, the diameters
of the abscesses in diabetic patients were more frequently
larger than 10 cm. In addition, the prevalence of multiple
abscesses in the DM group was higher than that in the non-
DM group. All of the results reveal that the outcomes of
PLA patients with DM are generally more severe than those
of the patients without DM.
A gas-forming abscess is a less common type of abscess
and is generally associated with a high mortality rate,
accounting for 7–24% of all PLA cases [23]. In this study,
gas-forming abscesses in the DM and non-DM groups
accounted for 11.4% and 5.0% of the PLA cases, respectively.
This difference was statistically signiﬁcant; therefore, DM
patients are more susceptible to gas-forming abscesses, and
this conclusion conﬁrms previous ﬁndings [12,23–28]. Dia-
betic patients, especially patients whose plasma glucose is
poorly controlled, provided a beneﬁcial environment for the
growth of gas-forming microorganisms. Gas formation occurs
as a result of mixed acid fermentation within abscesses by
formic hydrogenlyase, which is an enzyme produced by
microorganisms. Our study conﬁrmed the higher fatality rate
of gas-forming LAs. In our review, ﬁve patients out of the 28
patients who had a gas-forming abscess died of gas-forming
PLAs. The general fatality rate of gas-forming abscesses is
17.9%, which is different from previously reported results
[23,25]. The aetiology of the high fatality rate of gas-forming
PLAs is unclear.
During hospitalization, the most common complication
that occurred in both groups is bacteraemia, followed by
CVSO, reactive pleural ﬂuid (RPF), MODS and septic shock.
Our results are consistent with previously published reports
[12]. There is no statistically signiﬁcant difference between
the groups regarding the prevalence of bacteraemia and RPF,
whereas the prevalence of CVSO in both groups is statisti-
cally different, and this ﬁnding conﬁrms that DM is a risk fac-
tor for cardiovascular disease. The prevalence of MODS and
abscess recurrence in the DM group is higher than that in
the non-DM group. The total average febrifacient time
(t-AFT) and the duration of stay in the ICU of diabetic
patients are longer than those of the non-DM patients.
These ﬁndings suggest that the clinical features, pathophysio-
logical processes and prognoses of PLA patients with DM
are generally worse than those in patients without DM. This
result may be associated with the underlying immunocom-
promised condition of the DM patients.
Symptomatology of PLA
In this study, the most common symptoms were fever and/
or chills, followed by nausea and vomiting, RUQ pain and
general weakness. The typical triad of symptoms, including
reported fever, chills and abdominal pain, was present in less
than one-third of the patients in the two groups, and this
ﬁnding is comparable with other studies [3,12,15,18]. This
result may be related to the medications that were taken by
patients prior to their hospital admission. Compared with
non-DM patients, the temperatures of the patients with DM
were more frequently >38.5C, and the prevalence of SIRS
and shock was higher in the DM group. These data suggest
that the pathophysiological processes of PLAs in DM patients
are more severe than those in non-DM patients. In addition,
we observed that there were more PLA patients with DM
who presented with nausea and vomiting than patients with-
out DM. Nausea and vomiting often accompany ketoacidosis
in DM patients; therefore, these symptoms may be associ-
ated with underlying ketoacidosis in DM patients upon
admission to the hospital. Additionally, PLA patients may
present symptoms and signs, such as weight loss, abdominal
pain, diarrhoea, cough or dyspnoea, pleuritic or chest pain,
rales or rhonchi, hiccups, ascites, hepatomegaly, jaundice and
Murphy signs. These non-speciﬁc symptoms result in a
delayed diagnosis of PLA; therefore, physicians should treat
patients with these symptoms and signs promptly to prevent
catastrophic outcomes.
Laboratory and imaging ﬁndings of PLA
In this investigation, the most predominant haematological or
biochemical change in patients is CRP, which is an acute-
phase protein that is synthesized by liver endothelial cells. In
many studies, CRP has been demonstrated to be an ideal
marker in determining the usage of antibiotics and assessing
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the efﬁcacy of antibiotics. CRP is considered to be a valuable
indicator of inﬂammation [29–31]. In both groups, the CRP
levels of approximately all of the patients were >6 mg/L, and
these results are consistent with previous reports [12,17,32].
In addition, neutrophilic pleocytosis was present in both
groups. Approximately 80% of the diabetic patients had high
white blood cell counts (WBCc >10 000/dL), which were
signiﬁcantly different from those of the non-DM patients
(69.3%). However, the prevalence of elevated neutrophil
counts (>75%) in the DM group was lower than that in the
non-DM group, which could be the result of DM interfering
with neutrophil maturity, chemotaxis and phagocytosis
[20,21]. The blood tests for the PLA patients with DM and
without DM were similar: increased ALP, GGT and ESR; liver
function changes; leukocytosis; hypoproteinaemia; anaemia;
and prolonged PT. Most of the biochemical indicators were
not signiﬁcantly different between the groups; however, sig-
niﬁcant differences were found for albumin, ESR, serum glu-
cose and WBCc. The blood levels of BUN and Cr, which
are two parameters that indicate renal function in DM
patients, were signiﬁcantly different from those in the non-
DM patients. This ﬁnding revealed that PLA patients with
DM may have been more prone to contracting diabetic
nephropathy, which usually damages host renal function,
thereby increasing the blood levels of BUN and Cr.
We found that 88.6% of the diabetic patients and 90.1% of
the non-DM patients had elevated neutrophil counts, which
suggests that the neutrophil count is more sensitive than
WBCc in the diagnosis of PLA. The associated application of
these two biomarkers could assist physicians by reducing
misdiagnoses of PLA and unnecessary use of imaging analysis.
In addition, physicians should not exclude the presence of a
PLA in patients who have normal WBCc and liver function
tests. Remarkably, more than one-fourth of the patients pre-
sented with temple hyperglycaemia (>120 mg/dL) in the non-
DM group, and stress hyperglycaemia may have accounted
for this result.
Radiological examination is essential in the diagnosis of
PLAs. Approximately 30% of the patients had positive chest
X-ray ﬁndings. Pneumonia, right pleural effusion and elevated
right hemidiaphragm were the main complications that were
detected by X-ray. In this study, right pleural effusion and
elevated right hemidiaphragm resulted in a misdiagnosis of
PLA. In China, ultrasonography (US) and computerized
tomography (CT) are the most frequently employed diagnos-
tic modalities for PLAs. US and CT have demonstrated good
accuracy; however, US has limitations, particularly when the
abscesses are small, isoechoic and solitary. In this study, US
had a sensitivity of approximately 96%, which was higher
than that previously reported [33]. This sensitivity could
have resulted from the advanced diagnostic skills and afﬂuent
clinical experiences of the sonographers. Simultaneously, the
CT scan has a sensitivity of 98%, which is consistent with
previously published reports. Magnetic resonance imaging
(MRI) is generally employed as a stand-by option when a
diagnosis is unclear. Similar to the ultrasonic ﬁndings, the CT
results in positive patients usually show a hypodense area in
the liver. There are no conclusive differences between the
two groups according to the three imaging methods.
Bacteriology
In this study, K. pneumoniae was the most commonly isolated
aerobe in the blood and pus cultures, followed by E. coli
(Table 5 and 6). In the pus cultures, the rates of polymicrobial
infections in the DM and non-DM groups were 16 (12.2%)
and 14 (9.3%), respectively. Anaerobes accounted for 6.9%
of the infections in the DM group and 1.3% in the non-DM
group. This statistically signiﬁcant result demonstrated that
DM should be considered a high risk factor for anaerobic
infection. In the blood cultures, we observed that the rate of
positive growth was higher in DM patients than in non-DM
patients (73.9% vs. 53.6%). E. coli was more commonly iso-
lated in the non-DM group than in the DM group. In our
hospital, to increase the rate of a positive blood culture
when the body temperature of a patient was over 38.0C, a
blood sample was taken and cultured; therefore, there may
be bias in the result. Bacteroides fragilis was the most fre-
quently isolated anaerobic organism. In Europe [34] and
North America [3,12], the most common pathogenic bacte-
rium of PLAs is Streptococcus milleri; conversely, K. pneumo-
niae is the most commonly isolated pathogen in Asia,
especially in Taiwan [16,17,25,35–37]. Our ﬁndings con-
ﬁrmed the ﬁndings from previous studies.
The prevalence of PLAs due to K. pneumoniae has been
reported to be increasing worldwide [3,10,34,38–41]; how-
ever, the role of DM in the temporal shift in PLA epidemiol-
ogy remains to be elucidated. In the pus and blood cultures,
the prevalence of E. coli is higher in the non-DM group than
in the DM group, which may be correlated with the high
prevalence of BC or CC in the former. The systematic
microbiological data in this study conﬁrmed the previously
documented opinion that DM is a risk factor for gram-negative
bacteraemia, including episodes that are derived from
abdominal foci of infection. The underlying biological mecha-
nisms that are induced by DM may include tissue hyperglyca-
emia and a predilection for microorganisms, including
Klebsiella species and E. coli [10,42–44]. The major mecha-
nism for PLA development is the haematogenous seeding of
the liver, mainly through the portal system. In addition, the
circulation and local spread of infection within the abdominal
E324 Clinical Microbiology and Infection, Volume 18 Number 9, September 2012 CMI
ª2012 Lianxin Liu
ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E314–E330
cavity are common pathogenic pathways. SSTIs, furuncles
and carbuncles are observed in the past medical histories of
several PLA patients, and these ﬁndings suggest that metasta-
sis may play an important role in the pathogenesis of PLA.
In the bacteriological statistical results of this study,
enteric gram-negative rods, including Klebsiella species,
accounted for more than 80% of the PLA isolates; anaerobic
bacteria accounted for <10% of the isolates; and gram-posi-
tive cocci accounted for more than 10% of the isolates in
the non-DM group and <10% in the DM group. The most
common gram-positive cocci and enteric gram-negative rods
that were isolated from the pus of non-DM patients are Virid-
ians streptococci and Klebsiella species, respectively. The dif-
ference is statistically signiﬁcant. Compared with the non-
DM group, patients with DM were more prone to infection
with K. pneumoniae and anaerobes. These ﬁndings are com-
parable with those of previous studies of PLA [14,34,41,45].
Notably, other causes that were not as frequently detected,
such as hydatid origin and fungal causes, were predisposing
conditions for LAs in this present study. Moreover, we found
that DM was a medical condition that was associated with
FLAs. This result conﬁrmed similar conclusions that were
published in previous reports [46–48].
Bacterial drug resistance
K. pneumoniae and E. coli are the two most common patho-
gens in both groups; therefore, we conducted an additional
analysis of their microbiological characteristics. According to
the National Committee for Clinical Laboratory Standards
(NCCLS), we tested the susceptibility and resistance of the
two pathogens to the most commonly used antibiotics at the
clinic using standard biochemical tests. The bacteriological
statistical data indicated that the status of bacterial drug resis-
tance in the DM group was more severe than that in the
non-DM group, which suggests that DM was a potential cause
of resistance. This ﬁnding is consistent with previously pub-
lished conclusions [49]. The strains of E. coli that were iso-
lated from PLA patients are commonly resistant to most of
the ﬁrst-line antibiotics that are used at the clinic, and a high
rate of isolated E. coli strains was resistant to penicillins, qui-
nolones, aminoglycosides, and ﬁrst and second generation
cephalosporins, such as ampicillin, piperacillin, ciproﬂoxacin,
levoﬂoxacin, gentamicin, cefoxitin and cefuroxime. The preva-
lence of ESBL-positive E. coli strains that were isolated in the
DM group is higher than that in the non-DM group (p 0.005).
Many previous studies have demonstrated that the risk
factors for antibiotic resistance or multidrug resistance cor-
related with clinical conditions, such as inappropriate initial
empirical administration of antibiotics, increased antibacterial
use, antibacterial abuse, continued or irregular prior adminis-
tration of antibiotics before hospital admission, insufﬁcient
previous antimicrobial treatment, septic shock, haematologi-
cal malignancy, recent hospitalization, recent use of similar
antibacterial and mechanical ventilation and severe underlying
diseases, such as DM and end-stage renal disease [49–52]. In
addition, older age and underlying malignancy have been
demonstrated to be risk factors for the development of anti-
microbial-resistant isolates [27,53,54]. We did not investigate
the relationship between underlying malignancy, age and
MDR; however, we found that DM correlated with age
(p 0.024). Additionally, DM was associated with antibiotic
resistance. PLA patients with MDR were older than those
without MDR; therefore, age may be a risk factor for the
development of drug resistance. This conclusion is in agree-
ment with previously published results [55].
The resistance of the K. pneumoniae strains that were iso-
lated from PLA patients is signiﬁcant, and these isolated
strains are commonly resistant to most of the ﬁrst-line anti-
biotics, such as penicillins, quinolones, aminoglycosides and
ﬁrst and second generation cephalosporins (for example,
piperacillin, ampicillin, ciproﬂoxacin, levoﬂoxacin, gentamicin,
cefazolin and cefuroxime). Drug-resistant K. pneumoniae is
more prevalent in the DM group than in the non-DM group.
DM patients are generally immunocompromised, and their
ability to combat invasive bacterial infections is decreased,
which may compel physicians to increase the dosage of anti-
bacterial drugs and prolong the duration of drug administra-
tion. Consequently, the prevalence of bacterial drug
resistance increases. In China, inappropriate antimicrobial
treatment is a common health problem, especially in commu-
nity and private clinics and village, and town and country
hospitals. Antibiotics are often prescribed to treat individuals
even when the indications for the medication are lacking.
PLA patients who receive antibiotic treatment at these loca-
tions would be susceptible to antibiotic resistance. In addi-
tion, a delay in the initiation of appropriate antibiotic
treatment is another frequent health problem in China. This
inappropriate use of antibiotics has been demonstrated to be
associated with increased morbidity and mortality [56].
Similar reports on bacterial drug resistance are consistent
with these results; however, there were several discrepan-
cies [51,52,57]. The spectrum of the antimicrobial resistance
pattern in this study was different from that observed in
other hospitals [10], which may be correlated with the dif-
ferent policies regarding antibiotic use among the various
hospitals and bacterial variation. K. pneumoniae and E. coli are
the two most common pathogens of PLAs in this investiga-
tion. Regarding the antibiotic resistance proﬁle of these
pathogens and the high rate of resistance to antibiotics, the
choice of these antibiotics or similar antibiotics should be
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precluded in the initial empirical treatment of hospitalized
PLA patients upon admission. The broad spectrum of antimi-
crobial therapy and drug combinations should be recom-
mended and initiated before the pathogens are cultured and
identiﬁed. A report from Taiwan revealed that all of the iso-
lated K. pneumoniae strains from LAs remained susceptible to
quinolones, aminoglycosides, sulphamethoxazole-trimetho-
prim, and all of the b-lactam antibiotics, excluding ampicillin
and ticarcillin [10], and this conclusion is not consistent with
the results of our study. Regional disparities may have
accounted for the difference. In addition, the study in Taiwan
was conducted approximately 12 years ago, and the trend
for antimicrobial resistance has been drifted with policies
regarding the use of antibiotics.
The ﬁrst ESBL-producing strain of K. pneumoniae was doc-
umented in 1983 in Germany [58]. Subsequently, similar
reports from Europe and the US were published [59,60].
Although the current global prevalence of ESBLs is unknown,
their prevalence is increasing and their epidemic status is
severe. It has been reported that 10–40% of E. coli and
K. pneumoniae strains express ESBL in several parts of the
world [61]. In this study, we found that the ESBL-producing
strains of E. coli and K. pneumoniae were more common in
the DM group and the rate of ESBL that was expressed in
E. coli and K. pneumoniae is higher than that in the non-DM
group. These ﬁndings suggest that DM may be correlated
with the increasing rate of pathogenic ESBL-producing bacte-
ria. To the best of our knowledge, this is the ﬁrst report
that describes the statistically signiﬁcant differences in the
prevalence of ESBL-producing strains of E. coli and K. pneu-
moniae between DM and non-DM groups. The outcomes of
the patients who were infected with ESBL-producing organ-
isms are usually poor because these organisms generally
exhibit high-level resistance to antibacterials, which are used
to treat them, and the mortality rate in these ‘susceptibility/
treatment mismatched patients’ is higher [62–64]. ESBLs have
been isolated from a variety of Enterobacteriaceae and Pseudo-
monas aeruginosa [65,66]. We also found similar results in
this study, but being restricted to their rare isolates, we did
not investigate them further.
Therapeutic regimen
To date, there is no deﬁnite consensus on the treatment of
PLA. A report indicated that the effect of intermittent needle
aspiration was equivalent to continuous catheter drainage,
and needle aspiration was recommended as a ﬁrst-line drain-
age approach [16]. However, a study in Singapore on PLAs
that were >5 cm in diameter concluded that surgery pro-
vided better clinical outcomes than percutaneous drainage
(PD) [37]. Most clinicians employ image-guided PD as
ﬁrst-line treatment for PLAs whereas surgery is employed as
second-line treatment unless the conditions of the patient do
not allow surgery to be performed [67]. Surgery is reserved
only for severe or complicated cases, such as patients with
advanced malignancy or larger and multiloculated abscesses
[37]. PD and surgical treatments are not competing methods
but have their own indications. Surgery is an alternative
option for non-responders to percutaneous treatment. In this
study, three predominant measures were undertaken to treat
PLA: using antibiotics alone (Ab), combining percutaneous
drainage with antibiotics (PD + Ab) and combining surgery
with antibiotics (SG + Ab). In our hospital, initial empirical
antimicrobial treatment is provided as soon as a clinical diag-
nosis of PLA is made. The empirical administration of antibi-
otics is usually prescribed as piperacillin plus amikacin and
metronidazole, piperacillin/tazobactam plus metronidazole or
cefepime plus metronidazole. However, if a patient presents
the risk factors for infection with ESBL-producing organisms,
carbapenem antibiotics (e.g. imipenem, meropenem, ertape-
nem or doripenem) should be recommended before the cul-
ture and isolation results are obtained. Once the blood or
abscess ﬂuid cultures and bacterial isolation tests are con-
ﬁrmed, antibiotic regimens should be narrowed and pre-
scribed accordingly. On the basis of our clinical experience
and the results of this study, we propose the following treat-
ment algorithm: small (<5 cm) unliqueﬁed abscesses should
be treated with Ab alone; large (‡5 cm) uniloculated
abscesses should be treated with PD + Ab; and large multil-
oculated and complicated abscesses should be treated with
SG + Ab. Optimal measures should be selected according to
the condition of the patient, treatment response and the
characteristics of the PLA. In this study, 71.5% and 73.9% of
the PLA patients were treated with PD + Ab in the DM and
non-DM groups, respectively. The cure rates for the treat-
ments in the DM and non-DM groups are 90.3% and 92.0%,
respectively. The mortality of the PLA patients is 7.6% and
6.5% in the DM and non-DM groups, respectively, which is
similar to the ﬁndings in previous studies [1,12].
Therefore, treatment options should be determined on an
individual basis regardless of the presence of DM. We rec-
ommend the treatment of PLAs with PD + Ab as an optimal
regimen, and treatment with Ab alone or with SG + Ab can
be integrated when necessary.
Treatments and outcomes
As diagnostic imaging techniques, image-guided drainage
applications and new antibiotics have improved, the treat-
ments and outcomes of PLAs have signiﬁcantly improved
over the past several decades [16,68–71]. The mortality rate
of PLAs in our retrospective study is similar to previous
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studies [12,40,41], and DM is not one of the factors that
increases the fatality rate of PLAs. CVSO, multiple abscesses,
anaemia, uraemia, gas-forming abscesses, bacteraemia/septi-
caemia, polymicrobial infection, MDR, jaundice, total bilirubin
level, high BUN, hypoalbuminaemia and time in the ICU
(ICU-T) were all statistically signiﬁcant prognostic factors for
the mortality of PLAs in the univariate analysis. When these
signiﬁcant variables were obtained from the univariate analy-
sis and subjected to the multivariate analysis, uraemia, gas-
forming abscesses, MDR isolates and ICU-T were ﬁtted to
the stepwise logistic regression model. These results are in
agreement with the results from previous reports [12,26,27].
In this study, uraemia, gas-forming abscesses and MDR iso-
lates were associated with high mortality rates; however,
ICU-T was associated with the highest mortality rate. The
conditions of patients who are admitted to ICUs for an inde-
terminate duration are typically severe. A prolonged stay in an
ICU increases the probability of exposure to broad-spectrum
antibiotics, and opportunities for the cross-transmission of
resistant bacteria among patients. These outcomes may
explain why ICU-T was determined to be a prognostic factor
for mortality in the univariate and multivariate analyses. Our
analysis is consistent with previously published reports [72].
(Table 11).
Several limitations to this study should be acknowledged.
The study is retrospective, and all of the data were collected
from medical records. The patients were recruited from a
medical centre that is located in northeast China. Although
our results are comparable with a series of previous reports
in other countries and regions, the results from this study
may be incomplete. Therefore, more extensive analyses
should be conducted to conﬁrm the ﬁndings in this study.
We excluded PLA cases that originated from liver cancers in
the multivariate analysis, which may result in a deviation in
the results of the multivariate analysis. Because of restricted
research funding, we could only conduct a preliminary
review of the other types of LAs, such as FLAs, ALAs and
HsLAs; however, additional studies should be performed.
Because of the word count restrictions in this article, we
could not present more details regarding the other three
LAs; however, we will present these details in a separate
article. Several PLA patients were excluded from this study
because their medical treatment data were missing or
because they were transferred to other hospitals without
TABLE 11. Signiﬁcant factors related to mortality in 357 patients hospitalized with PLAs according to the univariate and mul-
tivariate analyses
Variables Category Mortality (%)
Univariate analysis Multivariate analysis
Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Diabetes mellitus Yes 12/158 (7.6) 1.2 (0.5–2.7) 0.696 – –
No 13/199 (6.5) 1.0
CVS occurrence Yes 7/47 (15.0) 2.8 (1.1–7.2) 0.049 10.9 (0.6–186.4) 0.099
No 18/310 (5.8) 1.0
Uraemia Yes 5/12 (41.7) 11.6 (3.4–39.8) <0.001 8.7 (1.5–51.4) 0.017
No 20/345 (5.8) 1.0
Multiple abscesses Yes 8/45 (17.8) 3.8 (1.5–9.3) 0.007 2.7 (0.7–10.3) 0.147
No 17/312 (5.4) 1.0
Bilobar involvement Yes 7/63 (11.1) 1.9 (0.8–4.8) 0.256 – –
No 18/294 (6.1) 1.0
Gas-forming abscesses Yes 5/28 (17.9) 3.4 (1.2–9.8) 0.048 7.6 (1.2–47.4) 0.030
No 20/329 (6.1) 1.0
Bacteraemia/septicaemia Yes 19/166 (11.4) 4.0 (1.6–10.2) 0.004 3.2 (0.8–13.2) 0.107
No 6/191 (3.1) 1.0
Polymicrobial infection Yes 6/34 (17.6) 3.4 (1.3–9.3) 0.028 5.9 (0.3–124.7) 0.254
No 19/323 (5.9) 1.0
MDR isolates Yes 14/87 (16.1) 4.5 (2.0–10.4) <0.001 4.8 (1.2–18.7) 0.024
No 11/270 (4.1) 1.0
Jaundice Yes 6/16 (37.5) 10.2 (3.3–30.9) <0.001 14.1 (0.2–973.5) 0.221
No 19/341 (5.6) 1.0
T. Bil ‡5 mg/dL 21/173 (12.1) 6.2 (2.1–18.5) <0.001 8.3 (0.1–525.4) 0.317
<5 mg/dL 4/184 (2.2) 1.0
BUN ‡22 mg/dL 10/126 (7.9) 1.2 (0.5–2.9) 0.610 – –
<22 mg/dL 15/231 (6.5) 1.0
Haemoglobin <12 g/dL 22/239 (9.2) 3.9 (1.1–13.3) 0.020 4.5 (0.8–24.7) 0.083
‡12 g/dL 3/118 (2.5) 1.0
Albumin <35 g/dL 10/64 (15.6) 3.4 (1.5–8.0) 0.007 6.4 (0.5–89.6) 0.168
‡35 g/dL 15/293 (5.1) 1.0
t-AFT ‡15 day 6/59 (10.2) 1.7 (0.6–4.4) 0.445 – –
<15 day 19/298 (6.4) 1.0
ICU-T ‡6 day 8/37 (21.6) 4.9 (2.0–12.4) <0.001 9.1 (2.5–33.4) <0.001
<6 day 17/320 (5.3) 1.0
OR, odds ratio; CI, conﬁdence interval; CVS, cardiovascular system; MDR isolates, multidrug-resistant isolates; T. Bil, total bilirubin; BUN, blood urea nitrogen; t-AFT, total
average fever time; ICU-T, stay in intensive care unit (days).
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complete treatment at our hospital, which may have resulted
in bias. Our analysis was restricted because the study was
hospital based, and LA patients who were not hospitalized at
our hospital were unintentionally excluded from the study,
which may have resulted in a deviation in the results of the
prevalence of LAs. Although the limitations in this study may
apply to other similar hospital-based studies, their effect on
the results of this study were probably minimal because our
hospital serves a large population of individuals.
There are several advantages to this study when com-
pared with previously published reports. The large and bal-
anced sample collection ensures that the ﬁndings from this
study have good generalizability and reliability. Our analysis
included a complete evaluation of the signs and symptoms,
underlying diseases, laboratory data, microbiological ﬁndings,
radiographic features, complications, treatments and out-
comes of LAs. This study was conducted in our hospital,
which is the largest institution in northeast China. Our insti-
tution is an over 3000-bed tertiary care teaching medical
centre that serves the Heilongjiang Province and several
regions of Inner Mongolia and the Jilin Province. Our hospital
provides more than 2 500 000 outpatient services, 220 000
emergency services and 30 000 surgical operations annually.
All of the data from our analysis were subjected to univari-
ate and multivariate analyses, in succession, and our conclu-
sions were based on these analyses. A logistic regression
model adjusted the results for other important factors,
which made our conclusions more precise and comprehen-
sive. We found that diabetic patients accounted for a high
rate of the patients in the cohort of FLA patients, which indi-
cated that DM plays an important role in the physiopatholog-
ical process of FLAs. We presented a clear proﬁle of the
antibiotic resistance of pathogenic bacteria in PLAs, and
reminded physicians that antibiotic resistance is a critical
condition in the area in which this study was conducted. The
data from this study suggest that third-generation cephalo-
sporin or broad-spectrum antibiotic therapy should be rec-
ommended as the initial treatment for PLAs. Our analysis
reveals that the microbiological spectrum of PLAs has
evolved, and the predominant pathogens of PLAs are
K. pneumoniae and E. coli.
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